Reports Net Revenues of $89.7 Million for the Three Months Ended December 31, 2018 RANCHO CUCAMONGA, Calif. , March 12, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months and full year ended December 31,
RANCHO CUCAMONGA, Calif. , March 07, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its fourth quarter of 2018 ended December 31, 2018 , after the market closes on Tuesday, March 12, 2019 , and will hold a conference call
RANCHO CUCAMONGA, Calif. , Jan. 03, 2019 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced today that Primatene ® MIST has been launched. Primatene ® MIST is an epinephrine inhalation aerosol bronchodilator suspension, which is the only FDA -approved metered dose
RANCHO CUCAMONGA, Calif. , Nov. 20, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Bill Peters , CFO will be presenting at the 30 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 1:30 p.m. Eastern Time , New York, NY .
RANCHO CUCAMONGA, Calif. , Nov. 09, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO will be presenting at the Jefferies London Healthcare Conference on Wednesday, November 14, 2018 at 2:00 p.m.
Reports Net Revenues of $75.5 Million for the Three Months Ended September 30, 2018 RANCHO CUCAMONGA, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended September 30, 2018 .
Primatene ® MIST fills unmet medical need as the only FDA approved over-the-counter asthma inhaler Primatene Mist RANCHO CUCAMONGA, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. , (NASDAQ: AMPH) announced today that the U.S.
RANCHO CUCAMONGA, Calif. , Nov. 02, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced that the Company will release results for its Third quarter of 2018 ended September 30, 2018 , after the market closes on Wednesday, November 8, 2018 , and will hold a conference
RANCHO CUCAMONGA, Calif. , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced today that Jason Shandell , President, and Bill Peters , CFO will be presenting at the Wells Fargo Healthcare Conference on Thursday, September 6, 2018 at 9:10 a.m.
Reports Net Revenues of $71.0 Million for the Three Months Ended June 30, 2018 RANCHO CUCAMONGA, Calif. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today reported results for the three months ended June 30, 2018 .
